M46 Management of CV Risk in Type 2 Diabetes

Program: Meet-the-Professor Sessions
Clinical Session
Saturday, March 7, 2015: 8:30 AM-9:15 AM
Room 33 (San Diego Convention Center)
**This session is eligible for CME credit**

Supported by Merck & Co., Inc.

Samuel Dagogo-Jack, MD, FRCP, University of Tennessee Health Science Center, Memphis,

SD: Principal Investigator, Astra Zeneca, Principal Investigator, Novo Nordisk, Consultant, Merck & Co., Principal Investigator, Boehringer-Ingelheim, Consultant, Novo Nordisk.